GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (OSTO:XSPRAY) » Definitions » Equity-to-Asset

XSpray Pharma AB (OSTO:XSPRAY) Equity-to-Asset : 0.91 (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is XSpray Pharma AB Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. XSpray Pharma AB's Total Stockholders Equity for the quarter that ended in Jun. 2024 was kr668.14 Mil. XSpray Pharma AB's Total Assets for the quarter that ended in Jun. 2024 was kr736.07 Mil.

The historical rank and industry rank for XSpray Pharma AB's Equity-to-Asset or its related term are showing as below:

OSTO:XSPRAY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.82   Med: 0.95   Max: 0.98
Current: 0.91

During the past 9 years, the highest Equity to Asset Ratio of XSpray Pharma AB was 0.98. The lowest was 0.82. And the median was 0.95.

OSTO:XSPRAY's Equity-to-Asset is ranked better than
87.19% of 1538 companies
in the Biotechnology industry
Industry Median: 0.67 vs OSTO:XSPRAY: 0.91

XSpray Pharma AB Equity-to-Asset Historical Data

The historical data trend for XSpray Pharma AB's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XSpray Pharma AB Equity-to-Asset Chart

XSpray Pharma AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.93 0.96 0.95 0.95 0.91

XSpray Pharma AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 0.94 0.91 0.89 0.91

Competitive Comparison of XSpray Pharma AB's Equity-to-Asset

For the Biotechnology subindustry, XSpray Pharma AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XSpray Pharma AB's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XSpray Pharma AB's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where XSpray Pharma AB's Equity-to-Asset falls into.



XSpray Pharma AB Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

XSpray Pharma AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=693.413/765.263
=

XSpray Pharma AB's Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Equity to Asset (Q: Jun. 2024 )=Total Stockholders Equity/Total Assets
=668.137/736.067
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XSpray Pharma AB  (OSTO:XSPRAY) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


XSpray Pharma AB Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of XSpray Pharma AB's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


XSpray Pharma AB Business Description

Traded in Other Exchanges
Address
Rasundavagen 12, Solna, SWE, 169 67
XSpray Pharma AB is a product development company with several product candidates in clinical development. It develops, sells and licenses generic versions of marketed cancer drugs, protein kinase inhibitors. The company primarily develops protein kinase inhibitors (PKI) are the largest segment within cancer drugs targeted for cancer treatment.

XSpray Pharma AB Headlines

No Headlines